

# Trusting Numbers



## A Hitch-hiker's Guide to Measurement Uncertainty in Laboratory Medicine

Professor Graham White

IFCC representative to JCGM WG1

Dept of Medical Biochemistry, Flinders University

SA Pathology, Flinders Medical Centre

Adelaide, Australia

### Medical laboratories:

Hundreds of different measurands

Many thousands of medical laboratories

Many millions of measurements/day



GH White

## Measurement results

Diagnosis

Disease - severity

- prognosis

- management

Therapeutic drug monitoring

Screening – disease, health

Safety – surgery, procedures

Research

Positive impact on quality of life and death

GH White

### JCGM-WG1 template for reporting the comments on JCGM 100:201X CD

Member organization (M.O.) or NMI :...IFCC.....

Please, fill in the Table sequentially according to the text

M.O. or NMI	Serial item No.	(Sub) clause (e.g. 4.1)	Paragraph No. / Line No. / Figure/Table/Note	Justification for change	Proposed change	Response of JCGM-WG1
	1	6.10	Line 2	Expansion of BIPM abbreviation not correct	Give meaning of abbreviation in original language, with English equivalent in parentheses if desired	
	2					
	3					
	Etc.					

GH White

## **ISO/IEC 17025**

### **ISO - 15189:2007: Medical laboratories – Requirements for quality and competence**

‘The laboratory shall determine measurement uncertainty  
for each measurement procedure in the examination phase....’

Field-specific guidance on estimating MU not available

Accreditation

Australia: Mandatory

2004:

Needed to develop a medical laboratory approach to MU

- based on ISO 17025, QUAM:2000 etc.

GH White

## Pathology Disciplines

Anatomical Pathology (Histopathology)

**Clinical Chemistry** – most prolific measuring discipline

Clinical Immunology & Allergy

Clinical Microbiology & Virology

Clinical Pharmacology

Haematology, Transfusion

Genetic Pathology

GH White

## A tale of three cultures

Assume results  
have  
required quality



Total Error Approach  
deeply embedded



A costly business



GH White

## Introducing MU to Australian medical laboratories



Mascot for introducing a proposed revision of the GUM?

The "wound man", indicating the various injuries from different weapons.  
From the Grosse Wundartzney, of Paracelsus, 1536.

GH White

## ISO 15189:2007 - GUM not a normative reference

GUM:

**1.4** It may be necessary to develop particular standards based on GUM that deal with the problems peculiar to specific fields...

GH White

**3.4.2** ..Because the .... model may be incomplete...**evaluation of uncertainty can be based as much as possible on observed data.**

**3.4.2.....use of long-term quantitative data**, ...and control charts that can indicate if a measurement is under statistical control, **should be part of the effort to obtain reliable evaluations of uncertainty.**

GH White

## Routine medical laboratories

‘Top-down approach’ to MU well-suited

No need for developing/testing models of MPs

No need for GUM high level maths/statistics

GH White

## GUM – Can usefully apply basic principles

Definition of the quantity intended to be measured (measurand)

Comprehensive description of the measurement procedure

Elimination of known significant bias

Systematic and random uncertainties treated same way

Uncertainty of results expressed as an absolute or relative SD

Interval of values around a measured value within which the ‘true’ value believed to lie, with stated level of confidence

Measured value is best estimate

GH White

## MU for the routine medical laboratory

GH White


### Request-Test-Report-Cycle



Many sources of uncertainty



GH White



Most measurands are measured once in a patient sample

GH White



How 'uncertain' can a patient result be,  
and still be clinically useful?



How are results interpreted?

GH White



Results are compared with:

biological reference intervals  
clinical decision values  
previous results


GH White

How sensitive are reference intervals to identifying normal/abnormal results?

GH White

### Reference intervals

Typically central 95% of 'healthy' values



Excludes 2.5 % 'presumed healthy' at each end

GH White




Fig. 2.1 Distribution of ALT measurements in 240 medical students.

From: Harris Ek, Boyd JC. Statistical Bases of Reference Values in Laboratory Medicine. Dekker Inc. 1995.





FIGURE 11-3. Frequency distribution of 100 gamma-glutamyltransferase (GGT) values.

From: Kringle & Bogovich in Tietz Textbook of Clinical Chemistry 3<sup>rd</sup> Edn.

## Real Data: non-Gaussian distributions


GH White



Reference interval insensitive to abnormality in the individual

Fraser CG. Biological variation, 2001, AACC Press

GH White




Personal means similar

Personal biological variation similar

Fraser CG. Biological variation, 2001, AACC Press

GH White



Modified from Gaw A et al. Clinical Biochemistry, Churchill Livingstone. 2003.

GH White

Reference intervals generally a 'rough' guide  
to whether a patient result is normal/abnormal

GH White

### Patient monitoring: Comparing serial results

PATIENT NAME		SAMPLED DATE			
Date:		14/10/13	31/03/14	17/10/14	06/05/15
Request Number:		37486439	39603081	40656269	42582596
HbA1c	(mmol/mol)	45	42	49	61
HbA1c	(%)	6.3	6.0	6.6	7.7
Method BIO-RAD Variat					

Need to know imprecision over long time for same MP

GH White


## Patient monitoring: Comparing serial results

Smallest quantitative change that must be reliably measured?

Need analytical goals (target uncertainties)

GH White

## Quality hierarchy for setting analytical goals



Target measurement uncertainties can be set

GH White

## IDEAL Approach to Estimating MU

For each MP in a laboratory :

- Define the measurand
- No modelling – use measured values to estimate MU
- Uncertainty of value assigned to end-user calibrator  $u_{cal}$
- Uncertainty of significant bias correction  $u_{bias}$
- Precision under intermediate conditions of reproducibility  $u_{inter}$

GH White

### Precision under intermediate conditions of reproducibility

For same MP in same laboratory:


Capture all unavoidable changes in measuring conditions

e.g. lot changes of reagents, calibrators  
different operators  
re-calibrations  
instrument maintenance

Will include e.g: electro-mechanical/temp fluctuations  
automatic value rounding  
environmental changes etc.

Use quality control (QC) data

GH White



2015: Current problems of estimating MU

GH White



## Defining the measurand

Physico-chemically well-defined analytes:

e.g. Na, K, Mg, D-glucose, cholesterol


Allows:

Primary reference materials

Reference measurement procedures

Result traceability to mole if calibrator commutable

GH White




## Defining the measurand

Poorly defined analytes e.g. Glycoprotein, steroid hormones

Multiple similar structures of 'same' hormone

GH White



Variable number  
side-chains on primary structure

Variable isoform proportions  
in individuals

Variable isoform recognition by  
different commercial MPs

GH White

Different methods use antibodies against different epitopes

**WHO Reference material  
'FSH' isoforms**

↑ ↑ ↑ ↑  
Different antibodies

**'FSH' method manufacturers**


Different FSH forms measured to different extents

Results from different FSH methods not  
equivalent

GH White


## FSH: EQA results from all Australasian Laboratories

All labs measuring samples of same human serum




Common clinical decision value: Menopause: FSH >20 mIU/L!

GH White



## hCG: EQA results from all Australasian Laboratories



1. Different kits detect different mixes of hCG variants?
2. Calibrators not commutable?

GH White

Ill-defined measurands suffer from:

No SI-traceable reference materials

No reference measurement procedures

and

Inadequate analytical selectivity


But are clinically valuable

GH White

End-user calibrators

Hierarchy of Traceability

GH White



## Summary



Many analytes:

- Inadequate definition of the measurand
- No high order reference materials
- No reference measurement procedures
- Use arbitrary measurement units (IU/L)
- WHO reference materials – no MU statement
- None, or incomplete  $u_{\text{cal}}$  from calibrator manufacturer

$u_{\text{cal}}$  – lacking or incomplete

GH White

Routine measurement procedures often  
lack analytical selectivity



Commonly used drug

30-70 % cross-reactivity in immunoassays for cortisol

GH White

Uncertainty of bias correction  $u_{\text{bias}}$

GH White

## Reference for bias assessment depends on measurand

- Secondary reference material or reference patient panel
- Trueness controls
- Target value for EQA peer group
- Inter-laboratory comparison

Bias and  $u_{\text{bias}}$  often not obtainable

GH White

## Summary so far

?  
Adequate definition  
of measurand

? ?  
$$u_c = \sqrt{(u_{\text{cal}}^2 + u_{\text{bias}}^2 + u_{\text{inter}}^2)}$$

GH White



Precision: intermediate conditions of reproducibility

GH White

Labs use Quality Control materials (QC)

Generally matrix-matched (human serum, plasma)


2-3 measurand concentrations across measuring interval

1-2 year supply

Measured when patient samples measured

Primary purpose: Assess MP performing to specification

GH White



Visualisation of MU for glucose measurement by single MP  
GH White

Use QC values to estimate MU of patient values

#### Validation


For similar measurand concentration:

Compare SDs of QC and panel of typical patient samples

Assume long-term QC imprecision data valid to estimate MU

GH White

?  
Adequate definition  
of measurand

? ?   
$$u_c = \sqrt{(u_{\text{cal}}^2 + u_{\text{bias}}^2 + u_{\text{inter}}^2)}$$

$u_{\text{cal}}^2$ ,  $u_{\text{bias}}^2$  generally not significant relative to  $u_{\text{inter}}$

For most measurands: estimated MU limited to imprecision

GH White

Reporting patient results

GH White



FLINDERS MEDICAL CENTRE  
FLINDERS DRIVE  
U.R. FMC - 01010630

DOB: 21/03/63 52 Years Sex: M  
Lab Ref: 15-44208945 MCH

Page 1 of 1

#### BIOCHEMISTRY

	18/03/15	22/03/15	10/04/15	11/04/15	12/04/15	13/04/15	14/04/15
Time	16:40	15:25	16:17	14:20	12:55	10:45	06:15
Lab No	40788383	43177231	43175101	43174963	44652003	43175180	44208945
Type	SERUM	SERUM	SERUM	SERUM	PLASMA	SERUM	PLASMA
Sodium (137-145)	mmol/L 135	132	127	128	133	136	137
Potassium (3.5-5.5)	mmol/L 3.9	3.7	4.5	3.7	3.9	4.3	3.9
Chloride (100-108)	mmol/L 101	99	95	93	101	101	103
Bicarb. (22-32)	mmol/L 26	27	28	29	23	27	24
Anion Gap (7-17)	mmol/L 12	10	8	10	13	12	14
Glucose (2.7-6.0)	mmol/L 4.9	5.6	4.7			5.6	
Urea (2.7-8.0)	mmol/L 3.9	2.5	2.7	2.4	1.8	1.8	2.3
Creatinine (50-120)	umol/L 83	87	61	69	68	74	72
eGFR mL/min/1.73m2	> 90	88	> 90	> 90	> 90	> 90	> 90
calc.Osmo							
Urate	mmol/L 0.31						
Phosphate	mmol/L 1.16	1.01	1.26			1.26	
Tot. Ca	mmol/L 2.31	2.36	2.28			2.43	
calc.iCa	mmol/L 1.19	1.24	1.21			1.25	
Albumin	g/L 42	40	38			42	
Glob.	g/L 25	27	27	28	29	25	
Protein	g/L 67	67	65	65	66	67	
Tot. Bilirubin	umol/L 9	9	8	8	3	7	
GGT	U/L 93	96	69	70	61	68	
ALP	U/L 82	87	71	69	61	63	
ALT							
AST							
LD							
CK							
Ma							
Am							
Lip							

Results assumed to be best estimates

No MU reported – available from lab

GH White

How do clinicians use quantitative laboratory results?

GH White


Single test result rarely 'stand-alone' evidence

Panels of related tests    Pattern of results over time


Results of related static/dynamic tests

Clinical history                      Clinical signs/symptoms

Imaging                      Other diagnostic information



**CLINICAL EXPERIENCE**



GH White

**Example of biochemical diagnosis - glucose**

Mr C - Clinical signs/symptoms → High blood glucose?

**WHO Guidelines:**

Random plasma glucose:  $\geq 11.1$  mmol/L

or


Fasting plasma glucose:  $\geq 7.0$  mmol/L

Plasma glucose:  $U = 0.2$  mmol/L; 95 % confidence

Within-individual biological variation (CV): ~5 5 %

GH White

EQA: Plasma glucose (SI traceable, primary RMP & RM)



### Example of improving result interpretation

Prostate specific antigen (PSA): If > 4.0 ug/L – biopsy?

GP:

My patient has a serum PSA of 4.2 ug/L – is it definitely high?

The PSA has gone from 3.6 to 3.9 over 5 months – significant?

$$u_{\text{rel}} \ 2 \%$$

Within-individual biological variation (CV): ~18 %

N.B. Personal biological variability >> relative standard MU

GH White

## CONCLUSIONS

GH White

### Advantages of using MU

- Overcomes limitations of total error approach, and simpler
- Set target uncertainties based on clinical requirements
- Quantitative evidence of meeting required clinical quality
- Improve interpretative advice to clinicians

Essential quality tool for medical laboratories

GH White

Problems of standardisation, harmonisation,  
traceability of patients measured values

International Federation of Clinical Chemistry  
Joint Committee for Traceability in Laboratory Medicine  
American Association of Clinical Chemistry  
European Federation of Laboratory Medicine  
+  
revision of ISO Standards

GH White

International aspirations:

Patients' results to be metrologically traceable to  
highest available references

Results for any given measurand to be equivalent regardless of  
the laboratory and measurement procedure used

MU use by medical labs and In-Vitro Diagnostic  
Manufacturers will increase in the future

GH White





GH White